The Severe Acute Respiratory Syndrome (SARS) drugs in development market research report provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Severe Acute Respiratory Syndrome (SARS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued products.
GlobalData tracks 42 drugs in development for Severe Acute Respiratory Syndrome (SARS) by 35 companies/universities/institutes. The top development phase for Severe Acute Respiratory Syndrome (SARS) is discovery with 21 drugs in that stage. The Severe Acute Respiratory Syndrome (SARS) pipeline has 37 drugs in development by companies and five by universities/ institutes. Some of the companies in the Severe Acute Respiratory Syndrome (SARS) pipeline products market are: CoV Biotechnology, Paint Therapeutics and Invivyd.
The key targets in the Severe Acute Respiratory Syndrome (SARS) pipeline products market include 2019 Novel corona Virus Spike Glycoprotein, Human SARS coronavirus Spike Glycoprotein, and Middle East Respiratory Syndrome coronavirus Spike Glycoprotein.
The key mechanisms of action in the Severe Acute Respiratory Syndrome (SARS) pipeline product include 2019 Novel corona Virus Spike Glycoprotein Inhibitor with five drugs in Preclinical. The Severe Acute Respiratory Syndrome (SARS) pipeline products include seven routes of administration with the top ROA being Intravenous and 17 key molecule types in the Severe Acute Respiratory Syndrome (SARS) pipeline products market including Monoclonal Antibody, and Small Molecule.
Severe Acute Respiratory Syndrome (SARS) overview
Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea, and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.
For a complete picture of Severe Acute Respiratory Syndrome (SARS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
